Have you been vaccinated with the hepatitis B vaccine, HEPLISAV-B, 28 days prior to or during your pregnancy?
If yes, you may be able to take part in the HEPLISAV-B Pregnancy Registry
Learn more by clicking on one of the following

Call the HEPLISAV-B Pregnancy Registry toll-free number 1-844-443-7734
OR email: heplisavbpregnancyregistry@ppdi.com
INDICATION AND IMPORTANT SAFETY INFORMATION

What is the HEPLISAV-B Pregnancy Registry?

The HEPLISAV-B Pregnancy Registry is an observational research study for women who were vaccinated with HEPLISAV-B within 28 days prior to conception, or during their pregnancy. The goal of the registry is to learn more about the health of infants born to mothers exposed to HEPLISAV-B during pregnancy. The information collected will provide doctors with an understanding of the effect (if any) of HEPLISAV-B exposure during pregnancy.

Ways to enroll in the HEPLISAV-B® Pregnancy Registry

Call Heplisav-B Pregnancy Registry
Call our toll-free number
1-844-443-7734
Download Participant Consent form
Download
Participant Consent to Contact Card
(Fill it out and send it to us via email or fax (1-877-202-3940))

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

  • Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
  • Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
  • Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
  • The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

References: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Emeryville, CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.

CLICK HERE FOR FULL PRESCRIBING INFORMATION
Visit www.HEPLISAV-B.com for more information.
Heplisav-B

© 2020 Dynavax Technologies. All rights reserved.

Privacy Policy | Terms of Use

US-20-00-00154